Table 1.
Pharmacokinetic, pharmacodynamic, and clinical complications of tramadol
| Parameter | Descriptions | |
|---|---|---|
| Absorption | Oral, SQ, injectable | |
| Excretion | Kidney | |
| Mechanism of action | μ-ORs, NE, and serotonin inhibition | |
| Therapeutic dose | 0.1–0.3 mg/l (adults); 1–2 mg/kg/dose (children) | |
| Lethal dose | 0.15–39 mg/l | |
| Pregnancy time | Category C | |
| Drug interaction | Antidepressants, digoxin, rifampin carbamazepine, MAOIs, quinidine | |
| Antidote | BZDs, naloxone | |
| Complications | Pupil | Miosis, mydriasis |
| Brain | Seizures | |
| Heart | Dysrhythmia | |
| Lung | Apnea | |
| Neurology | Serotonin syndrome | |
| Kidney | Renal failure | |
| Shoulder | Dislocation | |
| Muscle | Rhabdomyolysis | |
BZDs, benzodiazepines; MAOIs, monoamine oxidase inhibitors; NE, norepinephrine; μ-ORs, μ-opioid receptors; SQ, subcutaneous.